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1. Introduction 
Malignant pleural mesothelioma (MPM), typically associated with asbestos exposure, is an 
insidious neoplasm with findings of malignant unilateral pleural effusion or increase in 
pleural thickness (Jaurand and Fleury-Feith, 2005; Sterman and Albelda, 2005). Currently, 
imaging techniques such as computed tomography (CT) and magnetic resonance imaging 
(MRI) are widely used to evaluate the effects of chemotherapy on thoracic tumors. 
However, evaluation of the clinical response of MPM is difficult because it exhibits a non-
spherical growth pattern and irregular edges.  
MPM shows some technical problems to measure sizes of tumors in determining the 
response to chemotherapy. Cross-sectional CT or MRI appears inadequate for measuring the 
size of non-spherical tumors such as MPM. Response evaluation criteria in solid tumor 
(RECIST) criteria determine the method for measuring the longest diameter of the tumor 
(Therasse et al., 2000), but the appropriateness of these methods to MPM has not been 
determined. Recently, modified RECIST criteria were reported (Byrne and Nowak, 2004). 
Modified RECIST criteria determine the method of measuring tumor thickness 
perpendicularly to the chest wall or mediastinum in nonspherical tumors.  
In positron emission tomography (PET), altered glucose metabolism is visualized using the 
radiolabeled glucose analogue 18F-fluoro-2-deoxy-D-glucose (FDG). Evaluation of glucose 
metabolism using FDG-PET plays a critical role in early tumor diagnosis, staging, 
therapeutic strategy, and prognosis prediction (Kalff et al., 2001; Pieterman et al., 2000; 
Swisher et al., 2004; Vansteenkiste et al., 1998). FDG-PET imaging to evaluate responses to 
chemotherapy or irradiation is useful for patients with a variety of carcinomas (Kostakoglu 
and Goldsmith, 2003; Mac Manus et al., 2003). However, few studies involving MPM 
patients have been performed to assess the usefulness of FDG-PET for monitoring treatment 
responses (Ceresoli et al., 2006; Francis et al., 2007; Steinert et al., 2005; Veit-Haibach et al., 
2010). Here, we present a case involving the use of FDG-PET for monitoring responses to 
chemotherapy in a patient with MPM. FDG-PET and CT were performed before 
chemotherapy and after the first and second courses of chemotherapy. The tumor lesion 
exhibited shrinkage according to CT and a decrease in the SUVmax after the first course of 
chemotherapy, but exhibited size enlargement with an increase in SUVmax after the second 
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course of chemotherapy. These findings suggest that quantification of metabolic responses 
using FDG-PET may be related to the objective response as determined by modified RECIST 
in patients with MPM. We also discuss current data regarding FDG-PET in the clinical 
management of MPM.  
2. Case 
A 56-year-old non-smoking man was referred to our medical center for further examination 
of massive pleural effusion in the right lobe according to chest radiography. He had a 6-
month history of dyspnea and had been diagnosed with tuberculous pleuritis. He was 
treated with tuberculous drugs without improvement. His height was 162 cm, and his body 
weight was 63.5 kg, with no body weight loss in the preceding 6 months. He worked as a 
bus driver for 30 years without known asbestos exposure. Results of physical examination 
were nearly normal, and he exhibited no weakness of breath sounds in the right lung. 
Results of full hematological and biochemistry testing were all within normal limits, except 
for γGTP of 67 IU/L due to fatty liver. CRP was not elevated, and tumor markers CEA, NSE, 
and pro-GRP were all within normal ranges; CYFRA 21-1 was elevated to 6.7 ng/mL. A 
chest wall biopsy specimen obtained upon admission revealed biphasic-type MPM. Thoracic 
drainage of pleural effusion and OK-432 was performed. Pleural thickening was noted in 
the upper right hemithorax on chest computed tomography (Fig. 1a). FDG-PET scanning 
was performed as a part of a study of the usefulness of functional imaging of MPM at the 
Osaka City University Hospital (Osaka, Japan) (Kimura et al., 2008). FDG-PET imaging and 
CT scanning were performed before chemotherapy, as well as after the first and second 
courses of chemotherapy, with written informed consent.  
Upon completion of each scan, the patient was injected with intravenous FDG 185-370 MBq. 
The degree of FDG accumulation was evaluated using scanned images acquired 40 to 55 
minutes after injection. FDG was produced using an NKK-Oxford superconducting 
cyclotron and an NKK synthesis system (AMFG01, NKK, Muroran, Japan). PET images 
were obtained using a PET scanner (HEADTOME IV; Shimadzu, Kyoto, Japan) with 4 
detector rings providing 7 contiguous slices at 13-mm intervals and an intrinsic resolution of 
4.5-mm full width at half maximum (FWHM). Attenuation correction of reconstructed 
images was accomplished through a patient-specific transmission study using a 68 Ge ring 
source. FDG-PET images were compared with the corresponding CT images, allowing 
accurate identification of tumors by using anatomical landmarks. For quantitative 
evaluation, a region of interest (ROI) (circle 6 mm in diameter) was placed on the area of 
maximum FDG uptake within the lesion. A background ROI was then placed on a non-
tumorous region of the lung. The standardized uptake value (SUV), a quantitative measure 
of activity in the region of interest (ROI), was determined using the following formula:  
Radioactivity Concentration in ROI (Bq /mL)
SUV = 
Injected dose (Bq) / body weight (g)
 
He received chemotherapy with cisplatin and irinotecan. Severe diarrhea due to irinotecan, 
a different chemotherapy regimen, including cisplatin and docetaxel, was administered as a 
second course. The tumor lesion exhibited shrinkage according to CT images (Fig. 1), and 
SUVmax (Table 1) decreased after the first course of chemotherapy; however, size 
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enlargement and an increase in SUVmax after the second course of chemotherapy occurred. 
Progression-free survival and overall survival were 90 days and 320 days, respectively. 
 
Fig. 1. Monitoring chemotherapy response of malignant pleural mesothelioma using CT-
based modified RECIST criteria and FDG-PET-based SUVmax. CT and PET monitoring 
before chemotherapy (a), after the first course of chemotherapy (b), and after the second 
course of chemotherapy (c). Arrows show the target lesions.  
 
 a b c 
SUVmax 3.78 2.47 3.67 
Modified RECIST 10.38 6.45 10.08 
Table 1. Comparison of SUVmax and Modified RECIST in Fig 1.  
3. Brief reviews 
3.1 Differentiating malignant from benign disease 
Pleural disease has 3 fundamental pathologic features: effusion, thickening, and calcification 
of pleural surfaces, with overlapping radiological findings. Differentiation of malignant 
from benign lesions on the basis of clinical findings alone is often difficult. Furthermore, the 
results of thoracentesis, percutaneous biopsy, and even thoracotomy may be ambiguous, 
and nonfatal complications can occur in up to 10% of patients undergoing such procedures. 
FDG-PET imaging is highly accurate and reliable in differentiating malignant from benign 
pleural effusion and/or involvement (Gupta et al., 2002; Mavi et al., 2009). When an SUV 
cut-off of 2.0 was used to differentiate malignant from benign disease, a sensitivity of 91% 
and specificity of 100% were achieved, although the activity in some epithelial 
mesotheliomas was close to the threshold value (Benard et al., 1998). Another study found 
that PET scanning sensitivity was 96.8% and specificity was 88.5% in distinguishing benign 
from malignant pleural disease (Duysinx et al., 2004). Additionally, another study showed 
that a cut-off value of 2.2 for SUV provided the best accuracy, with 94.1% and 100% for 
sensitivity and specificity (Yildirim et al., 2009). Furthermore, the usefulness of dual time 
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point FDG-PET imaging in distinguishing malignant from benign localizing pleural disease 
has been reported (Mavi et al., 2009). The SUVmax and its change over time in MPM 
patients were significantly higher than those in the benign pleural disease group (P < 
0.0001). Yamamoto also described the usefulness of dual time point FDG-PET (Yamamoto et 
al., 2009). Sensitivity, specificity, and accuracy in detecting MPM by using both early and 
delayed PET were 88%. Mean values of SUVearly and SUVdelayed in MPM were 
significantly higher than the corresponding values in benign pleural disease (P < 0.01, 
respectively).  
We also treated a 66-year-old man with the benign pleural thickness with no tumor 
involvement. Pleural thickness was found during an annual check-up. He was an office 
worker and had smoked 20 cigarettes per day for 40 years; he had not been exposed to 
asbestos and did not complain of symptoms. However, his father had been exposed to 
asbestos for a long period of time. CT-guided needle biopsy of left side pleura revealed an 
increase in the collagen structure and infiltration of lymphocytes with no tumor 
involvement. CT, PET, and PET-CT images are shown in Fig. 2. Bilateral pleural thickness 
was shown in CT image(Fig 2a,c). Almost normal FDG uptake in the bilateral pleural 
thickness was shown in PET images (Fig 2b,d). A Biograph 16 (Siemens Medical, Germany), 
which has 39 detector ring providing 81 contiguous slices at 2-mm intervals, was employed 
for PET-CT examination.  
Thus, a combination of metabolic and anatomical information is useful for differentiating 
malignant from benign tissue. CT scans are most commonly used, although the use of PET 
scans has increased. Although multi procedures are valuable, false negative findings occur 
with both. These methods can be used in combination for a more accurate diagnosis. 
3.2 International TNM staging system for MPM 
For the past 30 years, several staging systems have been used for MPM. The TNM system is 
used to evaluate tumor size, lymph nodes, and distant metastasis. The clear need for an 
internationally accepted staging system prompted a group of International Mesothelioma 
Interest Group (IMIG) members to hold a consensus meeting in June 1994, and the new 
International TNM Staging System for MPM was developed as a result of this meeting. These 
guidelines reconcile the multiple previous staging systems, provide a staging system similar to 
those used for other solid tumors, and take into consideration recent data regarding the 
influence of T and N status on overall survival in MPM (Rusch, 1995). The TNM system of 
MPM consists of 4 stages. In Stage I, the MPM is in the membrane lining the chest (right or left 
pleura), and the MPM has not spread to the lymph nodes. In Stage II, the MPM involves the 
right or left pleura lining the chest. The MPM has also spread from the lining of the chest into 
the outer lining of the lung, into the diaphragm, or into the lung. In addition to involvement of 
the chest pleura, Stage III MPM has spread into the first layer of the chest wall, part of the 
mediastinum (the chest cavity behind the breastbone that lies between the lungs), or a single 
location in the chest wall. It may have also spread to the outer covering layer of the heart or to 
the lymph nodes on one side of the chest. In Stage IV MPM, the disease has advanced to other 
organs in the body such as the liver, brain, or bone or to lymph nodes on both sides of the 
chest. Tables 2 and 3 show TNM staging definitions and descriptions.  
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Fig. 2. Benign pleural thickness with no tumor involvement. PET-CT images of bilateral 
pleural thickness (narrow and large arrows). The trans-axial views of CT image (a), PET 
image (b) and PET-CT image (c), and coronal view of whole-body PET image (d). The 
SUVmax of the left side pleura (large arrow) and the right side pleura (narrow arrow) were 
2.019 and 1.452, respectively.  
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T  
T1a Tumor limited to the ipsilateral parietal pleura, including mediastinal and 
diaphragmatic pleura 
No involvement of the visceral pleura 
T1b Tumor involving the ipsilateral parietal pleura, including mediastinal and 
diaphragmatic pleura 
Scattered foci of tumor also involving the visceral pleura 
T2 Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, 
diaphragmatic, and visceral pleura) with at least one of the following features: 
involvement of diaphragmatic muscle 
confluent visceral pleural tumor (including fissures) or extension of tumor from 
visceral pleura into the underlying pulmonary parenchyma 
T3 Describes locally advanced but potentially resectable tumor 
Tumor involving all ipsilateral pleural surfaces (parietal, mediastinal, 
diaphragmatic, and visceral pleura) with at least one of the following features: 
involvement of the endothoracic fascia 
extension into the mediastinal fat 
solitary, completely resectable focus of tumor extending into the soft tissues of the 
chest wall 
nontransmural involvement of the pericardium 
T4 Describes locally advanced technically unresectable tumor 
Tumor involving all ipsilateral pleural surfaces (parietal, mediastinal, 
diaphragmatic, and visceral) with at least one of the following features: 
diffuse extension or multifocal masses of tumor in the chest wall, with or without 
associated rib destruction 
direct extension of tumor to the contralateral pleura 
direct extension of tumor to one or more mediastinal organs 
direct extension of tumor into the spine 
tumor extending through to the internal surface of the pericardium with or without 
a pericardialeffusion; or  
tumor involving the myocardium 
N  
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes 
N2 Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes, including 
the ipsilateral internal mammary nodes 
N3 Metastases in the contralateral mediastinal, contralateral internal mammary, 
ipsilateral, or contralateral supraclavicular lymph nodes 
M  
MX Presence of distant metastases cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
Table 2. New International Staging System for diffuse MPM 
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Stage T N M 
I T1 N0 M0 
Ia T1a N0 M0 
Ib T1b N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
 T1,T2 N2 M0 
 T3 N0,N1,N2 M0 
IV T4 Any N M0 
 Any T N3 M0 
 Any T AnyN M1 
Table 3. Stage by tumor (T), lymph node (N), metastasis (M), and Description of 
International TNM staging system for diffuse MPM 
3.3 PET for staging and preoperative evaluation for MPM 
The combination of metabolic and anatomical information provided by PET is useful in 
determining the stage and conducting a preoperative evaluation of MPM. Recent studies 
indicate the potential in the use of PET in diagnosing MPM and determining MPM staging 
or the extent to which tumors have spread. In a comparative study by Plathow et al., the 
diagnostic values of CT, PET, PET/CT, and MRI for staging were evaluated in 54 patients 
with limited MPM (Plathow et al., 2008). The accuracies of CT, PET, MRI, and PET/CT were 
0.77, 0.86, 0.8, and 1.0, respectively, for limited MPM patients, and 0.75, 0.83, 0.9, and 1.0, 
respectively, for patients in Stages II and III. FDG-PET/CT is significantly more accurate in 
Stages II and III compared with all other techniques.  
In addition, FDG-PET is particularly useful for identifying occult distant metastases. 
Twenty-eight consecutive patients referred for the evaluation of suspected MPM underwent 
FDG-PET imaging at the University of Pennsylvania Medical Center (Benard et al., 1998). 
PET imaging was compared with thoracoscopy and surgical biopsies and was found to 
successfully indicate the presence of disease in 24 patients and of benign conditions in the 
remaining 4 patients. FDG uptake was significantly higher in diseased cells, and PET 
analysis showed tumors in the lymph nodes of 9 patients. Lymph nodes appeared normal 
based on CT scans. Another study at Brigham and Women’s Hospital and Harvard Medical 
School in Boston evaluated 15 patients, 11 of whom had MPM and 4 who were disease–free 
(Gerbaudo et al., 2002). PET results were compared with laboratory analysis of biopsied 
fluids and tissues. PET was used to detect all 11 primary tumors and confirm the absence of 
disease in the other 4 patients. For biopsied lesions, overall sensitivity, specificity, and 
accuracies for FDG-PET were 97%, 80%, and 94%, respectively, compared with 83%, 80%, 
and 82%, respectively, for CT. FDG-PET was used to identify extrathoracic metastases in 5 
patients, excluding these patients from surgical therapy. Sorensen et al. compared the 
accuracy of preoperative staging with different imaging modalities and found that non-
curative surgery could be avoided in 29% of 42 MPM patients using preoperative PET/CT 
and in another 14% by employing mediastinoscopy (Sorensen et al., 2008). Wilcox et al. 
reported the utility of PET/CT in the initial staging and assessed 35 patients with MPM 
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included in the Mayo clinic database. PET/CT excluded 14 of 35 patients from surgical 
intervention (Wilcox et al., 2009). Upstaging from PET/CT was noted in 70% of patients 
when surgical pathology was available.  
These studies indicate that although CT scans are a standard test for evaluating MPM 
patients, PET can also be used for MPM diagnosis. PET/CT increases staging accuracy in 
patients with MPM and improves patient selection for curative surgical procedures. Distant 
metastases have historically been considered to be an uncommon late manifestation of MPM 
(Truong et al., 2006). But, accurate determination of the presence or absence of distant 
metastases is crucial for potentially curative surgical resection of MPM. 
3.4 PET for restaging and survival 
Accurate restaging of disease after treatment has also implications for survival. Two 
retrospective studies have concluded that FDG-PET/CT is useful for detecting metastases. 
The first was reported by Tan et al. and involved the evaluation of 44 patients using 
PET/CT after multimodality therapy for MPM (Tan, 2010). The other study was reported by 
Lee and was a retrospective study involving 46 patients who were evaluated using PET/CT 
for staging or re-staging after therapy for MPM (Lee et al., 2009). Both studies concluded 
that detecting extrathoracic metastases using FDG-PET/CT indicates poor prognosis in 
patients with MPM.  
A correlation between PET parameters and prognosis has been shown in some reports. 
Nowak et al. reported that 93 patients underwent PET/CT assessments at baseline; these 
patients were then treated clinically and survival was followed (Nowak et al., 2010). In 
univariate analysis, significant prognostic factors included total glycolytic volume (TGV), 
sarcomatous history, weight loss, CT stage, and European Organization for Research and 
Treatment of Cancer (EORTC) good prognosis category. In multivariate analysis, TGV and 
weight loss remained as significant prognostic factors in patients with non-sarcomatoid 
histology and no pleurodesis. Gerbaudo et al. reported 50 patients subjected to PET/CT 
assessments after therapy, and survival after relapse was independently predicted based on 
the pattern of FDG uptake and PET nodal status; overall survival was predicted based on 
the maximum standard uptake value (Gerbaudo et al., 2011). 
3.5 PET for response assessment 
3.5.1 Modified RECIST criteria 
Modified RECIST criteria have been published with particular reference to MPM (Byrne and 
Nowak, 2004). Response to treatment is evaluated by measuring uni-dimensional tumor 
thickness perpendicular to the chest wall in 2 positions at 3 different levels on CT. The sum 
of these 6 measurements is defined as the pleural uni-dimensional measure. Transverse cuts 
at least 1 cm apart and related to anatomical landmarks in the thorax were chosen to allow 
reproducible assessment at later time points. If a measurable tumor was present, transverse 
cuts in the upper thorax, above the level of the main bronchi division were preferred. At 
reassessment, pleural thickness was measured at the same position and at the same level by 
the same observer. This measurement did not necessarily represent the greatest tumor 
thickness at the level. Nodal, subcutaneous, and other bi-dimensionally measurable lesions 
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were measured uni-dimensionally based on the RECIST criteria. Uni-dimensional 
measurements were included to obtain the total tumor measurement. The RECIST definition 
is listed in Table 4. A confirmed response required repeat observation on 2 occasions 4 
weeks apart. 
 
Complete response  
(CR) 
Disappearance of all target lesions with no evidence of tumors 
elsewhere 
Partial response 
(PR) 
At least a 30%reduction in the total tumor measurement 
Progressive disease 
(PD) 
Increase of at least 20% in the total tumor measurement over 
the nadir measurement or the appearance of one or more new 
lesions 
Stable disease 
(SD) 
Those who fulfilled the criteria for neither PR and PD 
Table 4. Response criteria of Modified RECIST 
3.5.2 PET in RECIST version 1.1 
Currently, most clinical trials evaluating cancer treatments for objective responses in solid 
tumors are using RECIST. The RECIST Working Group, consisting of clinicians with 
expertise in early drug development from academic research organizations, government, 
and industry, together with imaging specialists and statisticians, has met regularly to set an 
agenda to update RECIST, determine the evidence needed to justify various changes made, 
and to review emerging evidence (Eisenhauer et al., 2009). RECIST 1.1, published in January 
2009, is an update to the original criteria. A critical aspect of the revision process was to 
create a database of prospectively documented solid tumor measurement data obtained 
from industry and academic group trials. However, the Working Group and particularly 
those involved in imaging research, did not believe that there was sufficient standardization 
and widespread availability to recommend adoption of either volumetric anatomical 
assessment or to functional assessment (e.g. dynamic contrast enhanced MRI, CT, or FDG-
PET techniques assessing tumor metabolism). The only exception to this is the use of FDG-
PET imaging as an adjunct to determine progression. The RECIST Working Group looks 
forward to such data emerging in the next few years to allow appropriate changes to be 
made to the next iteration of the RECIST criteria. 
3.5.3 PERCIST— Positron Emission tomography Response Criteria In Solid Tumors 
Therapy monitoring with FDG-PET is generally based on consensus criteria from the 
European Organization for Research and Treatment of Cancer (EORTC) (Young et al., 1999). 
Based on the extensive literature now supporting the use of 18F-FDG PET as well as the 
known limitations of anatomic imaging to assess early treatment response, updated draft 
PET criteria have been proposed that may be useful for consideration in clinical trials and 
potentially in clinical practice. We refer to these draft criteria as “PERCIST”—Positron 
Emission tomography Response Criteria In Solid Tumors (Wahl et al., 2009). The premise of 
the PERCIST 1.0 criteria is that cancer response as assessed by PET is a continuous and time-
dependent variable. A tumor may be evaluated at a number of times during treatment and 
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glucose use may rise or fall from baseline values. SUV will likely vary for the same tumor 
and the same treatment at different times. For example, tracer uptake by a tumor is expected 
to decline over time with effective treatment. Thus, capturing and reporting the fractional 
change in SUV from the starting value and when the scan was obtained are important. 
 
Complete metabolic 
response  
(CMR) 
Complete resolution of 18F-FDG uptake within a measurable target 
lesion such that it is less than the mean liver activity and 
indistinguishable from surrounding background blood-pool levels. 
Disappearance of all other lesions to background blood-pool levels. 
Partial metabolic 
response 
(PMR) 
Reduction by a minimum of 30% in target measurable tumor 18F-
FDG SUL peak. Absolute drop in SUL must be at least 0.8 S UL 
units as well. Measurement is commonly in same lesion as baseline 
but can be another lesion if that lesion was previously present and 
is the most active lesion after treatment. Reduction in the extent of 
tumor 18F-FDG uptake is not a requirement for PMR. 
Progressive metabolic 
disease 
(PMD) 
>30% increase in 18F-FDG SUL peak, with >0.8 SUL unit increase in 
tumor SUV peak from baseline scan in pattern typical of a tumor 
and not of infection/treatment effect OR: visible increase in extent 
of 18F-FDG tumor uptake (75% in TLG volume with no decline in 
SUL OR: new 18F-FDG–avid lesions. 
Stable metabolic 
disease 
(SMD) 
Not CMR, PMR, or PMD. 
Table 5. Response criteria of PERCIST 
Patients should fast for at least 4 to 6 h before undergoing scanning, and the measured 
serum glucose level (no correction) must be less than 200 mg/dL. Patients may be on an oral 
hypoglycaemic but not on insulin. A baseline PET scan should be obtained 50 to 70 min after 
tracer injection. A follow-up scan should be obtained within 15 min (but always 50 min or 
later) of the baseline scan. All scans should be performed using the same PET scanner with 
the same injected dose ±20% of radioactivity. Appropriate attenuation correction along with 
evaluation for proper PET and CT registration of the quantitated areas should be performed. 
Lean body mass (SUL) is determined for up to 5 tumors (up to 2 per organ) with the most 
intense 18F-FDG uptake. These will typically be lesions identified using RECIST 1.1. The 
SUV peak (this is a sphere with a diameter of approximately 1.2 cm to produce a 1-cm3-
volume spherical ROI) centered near the hottest point in the tumor foci should be 
determined and the image planes and coordinates should be noted (SUL peak). This SUL 
peak ROI will typically include the maximal SUL pixel (which should also be recorded) but 
is not necessarily centered on the maximal SUL pixel. Tumor sizes should be noted and 
should be 2 cm or larger in diameter for accurate measurement, although smaller lesions of 
sufficient 18F-FDG uptake, including those not well observed anatomically, can be assessed. 
Each baseline (pretreatment) tumor SUL peak must be 1.5 × mean liver SUL + 2 SDs of mean 
SUL. If the liver is diseased, 2.0 × blood-pool 18F-FDG activity + 2 SDs in the mediastinum is 
suggested as the minimal metabolically measurable tumor activity. In PERCIST, the 
response to therapy is assessed as a continuous variable and expressed as the percentage 
change in SUL peak (or sum of lesion SULs) between pre- and post-treatment scans. After 
www.intechopen.com
 Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma 
 
285 
chemotherapy, waiting a minimum of 10 d before performing FDG-PET is advised. This 
time permits bypassing of the chemotherapeutic effect and of transient fluctuations in 18F-
FDG uptake that may occur early after treatment, including stunning or flaring of tumor 
uptake. The response criteria are listed in Table 5. 
3.6 PET for therapeutic response assessment in MPM 
PET and CT examinations can play important roles in the management of patients with MPM. 
Particularly, an emerging role for FDG-PET/CT is that of therapeutic response assessment. 
Steinert et al. performed assessments on 17 patients after 3 cycles of chemotherapy and 
reported that total lesion glycolysis (TLG), defined as (SUVmax) × (Vol), more accurately 
identifies patients responding to chemotherapy (Steinert et al., 2005). Ceresoli et al. measured 
CT and PET responses in 22 patients after 2 cycles of chemotherapy and found that an early 
metabolic response as a 25% decrease in SUVmax was significantly correlated to median time-
to-tumor progression and was tended to be associated with longer overall survival (Ceresoli et 
al., 2006). Francic et al. reported a prospective study, including patients who had undergone 
both FDG-PET and conventional radiological response assessment before and after 1 cycle of 
chemotherapy (Francis et al., 2007). Twenty-three patients were evaluated and a statistically 
significant relationship between a fall in TGV and improved patient survival was shown. Veit-
Haibach et al. reported a study involving 41 patients evaluated by FDG-PET/CT at baseline 
and after 3 cycles of pemetrexed plus platinum-based chemotherapy (Veit-Haibach et al., 
2010). Neither SUVmax-response nor SUVmean-response was related to survival; however, a 
decrease in TLG and PETvol was found to be significantly predictive of survival. Flores et al. 
reported a statistically significant association between a decrease in SUV after chemotherapy 
and overall survival in 24 MPM patients treated with cisplatin-based induction chemotherapy 
and surgery (Flores et al., 2005).  
Our group conducted a small study involving 11 patients with MPM (Kimura et al., 2005). 
FDG-PET scanning was performed at the Osaka City University Hospital (Osaka, Japan) as 
part of a prospective study to examine the usefulness of functional imaging of MPM. This 
study was conducted between March 1999 and December 2004 and all patients had a proven 
histological diagnosis of MPM treated using chemotherapy. Each patient underwent both 
FDG-PET imaging and CT scanning before treatment and after the first courses of 
chemotherapy. Written informed consent was obtained from all patients. A total of 33 
lesions in 11 patients with MPM were studied. The Spearman rank correlation test was used 
to compare ratios of pre-therapy to post-therapy SUVs. In an examination of CT evaluation, 
the mean SUV of the 8 lesions exhibiting a clinical response after the first course of the 
chemotherapy significantly decreased from 4.03 + 1.28 SD to 2.83 + 0.69 SD (P = 0.050) (Fig. 
3a). The mean SUV of the 5 lesions exhibiting clinical progression after the first course of 
chemotherapy tended to increase from 2.42 + 0.90 SD to 2.74 + 0.88 SD (P = 0.072) (Fig. 3b). 
The mean SUV of the 20 lesions exhibiting no clinical change after the first course of 
chemotherapy significantly decreased from 3.71 + 1.85 SD to 3.03 + 1.63 SD (P = 0.0002) (Fig. 
3c).  
Thus, some PET parameters used to evaluate metabolic response may be associated with 
overall survival as well as predict anatomical response. The differences between these 
studies are the timing of assessments for early evaluation of metabolic response. The best 
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timing and best parameters in patients with MPM remain to be clearly determined. Further 
clinical studies are necessary to determine the usefulness of FDG-PET as a monitoring 
method for response to chemotherapy. 
 
Fig. 3. FDG uptake (SUV) changes assorted to CT responses. Lesions exhibiting clinical 
response (a), clinical progression (b), and without change (c) before and after the first course 
of chemotherapy.  
4. Limitations and pitfalls 
FDG-PET has been reported to yield false-negative results for lesions smaller than 1 cm and 
false-positive results for lesions with inflammatory change (Kostakoglu and Goldsmith, 
2003). In the current state of technology, it is impossible to detect small clusters of tumor 
cells that will cause a clinically detectable recurrence of disease in the future 
(Hueltenschmidt et al., 2001). Tumors exhibit heterogeneous biological activity in single 
tumors; however, it is difficult to obtain cytological and histological materials from patients 
with MPM from multiple lesions at multiple time points and histological confirmation of 
metabolic response. Unfortunately, in this chapter, it has been impossible to cite all 
references referring to the use of FDG-PET in MPM. 
5. Conclusion  
The present case suggests that the results of quantification of metabolic response by FDG-
PET may be related to objective response as determined by modified RECIST in patients 
with MPM. It also is important to acknowledge that SUVs are not strictly quantitative, and 
repeated biopsies are sometimes required. Information derived from FDG-PET during 
treatment may require assessment based on standard follow-up procedures. Final 
interpretations of images reported are based on total analysis and not SUV alone.  
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